Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 14Terminated 2Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 98Lymphoid 48Other hematologic neoplasm 37Thoracic 7Genitourinary 6Gastrointestinal 5CNS 4Breast 4Tumor-Agnostic 3Myeloid 3Gynecologic 2Other solid neoplasm 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Paclitaxel 81Carboplatin 67pembrolizumab 62Bevacizumab 58Cisplatin 49Specimen Handling 29Drug Therapy 26Blood Specimen Collection 23olaparib 20Cyclophosphamide 18Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14Brachytherapy 14fludarabine 13Radiotherapy 13abemaciclib 12Injections 12Topotecan 11Nivolumab 11Doxorubicin 11lenvatinib 10Fulvestrant 10Fluorouracil 10Surveys and Questionnaires 9Standard of Care 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Dexamethasone × Gynecologic × Clear all
NCT06824467 2026-05-08

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Eisai Inc.

Phase 1/2 Recruiting
182 enrolled
BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡